根据循证证据强化降糖,保护β细胞,减少心血管疾病风险

作为经济迅速发展中的国家,中国糖尿病患病人数在迅速增加,并且发病年龄不断年轻化.其血管合并症是糖尿病致残致死的主要原因.     

中国门诊2型糖尿病患者口服药降糖达标状况调查及格列齐特缓释片优化治疗效果分析

Objective To evaluate the current state of glycemie control in Chinese patients with type 2 diabetes mellitus who have received oral antidiabetic agents in the out-patient clinic,and the efficacy and safety of optimized regiments of gliclazide modified-release tablets (Diamicron MR, SERVIER, Tianjin) in patients with failed glycemic control (HbA1c 6.5%). Methods The patients with type 2 diabetes were enrolled from 54 hospitals in more than 20 cities and received long-term (more than 3 months) oral antidiabetic agents. HbA1c was measured and the success rate of HbA1c reduction was evaluated. The patients who failed to achieve glycemic control (HbA1c 6. 5%) and received daily multiple-dosing insulin secretagogues were provided with the optimized treatment regimen, consisting of replacing daily multiple-dosing insulin secretagogues with single-dosing gliclazide sustained-release tablets. Clinical efficacy and safety were evaluated after three months treatment. Results The survey of glycemic control revealed that the mean HbA1c of 5 586 patients with diabetes mellitus was (7.97±2.89)% ,and the success rate (HbA1c≤6.5%) was 14. 1%. Further more, HbA1c decreased from (8.23±4.00)% before optimization to (6.86±2.24)% after optimization with the average decrement of 1.37% (P<0. 001) and the success rate was raised to 34. 1%. The gliclazide modified-release tablets were well tolerated by most patients, only 2.6% of whom were reported to experience unconfirmed hypoglycemia. Conclusion The success rate of glycemic control was low in Chinese out-patients with type 2 diabetes mellitus receiving oral antidiabetic agents in the clinic. The optimized regimen of gliclazide modified-release tablets taken once daily can down-regulate glycemic levels and increase the success rate of HbA1c reduction,and thus plays efficiently and safely a key role in the optimized management of type 2 diabetes mellitus.     

B.BRAUN Omnitest~电子感应血糖仪临床验证报告

糖尿病代谢控制的重要内容为血糖监测 ,由于其直接关系到糖尿病的治疗 ,因此测血糖方法的准确性和便利程度一直是临床医生十分关注的问题。本文对 B.BRAUN Omnitest○R电子感应血糖仪的精确性进行了评估 ,探讨其精确性和准确性。方法一、试验材料血糖标本来源 :全部标本取自来门诊就诊的 2型糖尿病病人 10 0例 ,事先征得病人同意。全部患者采空腹血 ,其中 5 0例同时采餐后 2小时血 ,将静脉血标本置于氟化钠抗凝管中 ,用葡萄糖氧化酶法在生化分析仪上测定静脉血浆血糖 (VPG)。同时立即采受试者毛细血管血一滴 ,用 B.BRAU N Omnitest…     

胸腔镜肺减容术治疗慢性阻塞性肺气肿30例临床研究

目的 探讨胸腔镜肺减容术治疗慢性阻塞性肺气肿的临床效果.方法 采用回顾性分析方法,分析我院2011年5月至2013年6月牧治的30例行胸腔镜肺减容术治疗的慢性阻塞性肺气肿患者的临床资料.结果 30例患者均手术顺利,气促症状改善明显.未发生切口感染、呼吸衰竭、心力衰竭等并发症,患者均恢复良好.结论 胸腔镜下肺减容术能够有效缓解慢性阻塞性肺气肿患者的呼吸困难等症状,改善患者的生活质量,具有一定的临床意义.     

丹红注射液配合莫沙必利治疗糖尿病性胃轻瘫120例

目的 探讨中西医联合治疗糖尿病性胃轻瘫的疗效.方法 以控制饮食、加强运动为基础,对照组应用胰岛素和/或降糖药及口服莫沙必利,治疗组在此基础上加丹红注射液.结果 两组患者相比,治疗组总有效率优于对照组,差异有统计学意义（P＜0.05）.结论 丹红注射液使微循环障碍得以改善,起到疏通经脉的作用,而莫沙必利加强胃排空,两者结合,取得了明显的疗效.     

提高服务质量减少护患矛盾的对策

通过对引发护患矛盾的原因分析，提出相应的护理对策。使护理人员从思想和行动上转变服务意识和观念，端正服务态度，提高服务质量。     

标本保存条件对尿微量白蛋白测定的影响

微量白蛋白尿筛查的可靠性受检测方法本身及标本保存条件的影响。非胰岛素依赖性糖尿病（ｎｏｎｉｎｓｕｌｉｎｄｅｐｅｎｄｅｎｔｄｉａｂｅｔｅｓｍｅｌｉｔｕｓ，ＮＩＤＤＭ）患者４６例，留取１０ｐｍ至次日６ａｍ尿，分为加防腐剂ＮａＮ３组及不加防腐剂组，离心后...     

内分泌疾病专题讲座——第五讲 肾上腺皮质机能亢进性疾病(一)

肾上腺皮质包括外层球状带,分泌盐类皮质激素,主要是醛固酮;中层最厚为束状带,分泌糖皮质激素,以皮质醇为主;内层为网状带,分泌性激素。当这些部位发生肿瘤或增生时出现相应激素分泌增多的表现。皮质醇增多症最常见,原发性醛固酮增多症次之。     

德谷门冬双胰岛素——理想的新一代基础餐时双胰岛素制剂

德谷门冬双胰岛素制剂由新一代超长效基础胰岛素类似物（德谷胰岛素）联合餐时胰岛素类似物（门冬胰岛素）组成。其能够更好地模拟生理性胰岛素分泌模式,更安全有效地控制空腹和餐后血糖,成为理想的新一代基础餐时双胰岛素制剂。